| Literature DB >> 34637683 |
Hemant Joshi1, Divya Kandari1, Rakesh Bhatnagar1,2.
Abstract
The establishment of persistent infections and the reactivation of persistent bacteria to active bacilli are the two hurdles in effective tuberculosis treatment. Mycobacterium tuberculosis, an etiologic tuberculosis agent, adapts to numerous antibiotics and resists the host immune system causing a disease of public health concern. Extensive research has been employed to combat this disease due to its sheer ability to persist in the host system, undetected, waiting for the opportunity to declare itself. Persisters are a bacterial subpopulation that possesses transient tolerance to high doses of antibiotics. There are certain inherent mechanisms that facilitate the persister cell formation in Mycobacterium tuberculosis, some of those had been characterized in the past namely, stringent response, transcriptional regulators, energy production pathways, lipid metabolism, cell wall remodeling enzymes, phosphate metabolism, and proteasome protein degradation. This article reviews the recent advancements made in various in vitro persistence models that assist to unravel the mechanisms involved in the persister cell formation and to hunt for the possible preventive or treatment measures. To tackle the persister population the immunodominant proteins that express specifically at the latent phase of infection can be used for diagnosis to distinguish between the active and latent tuberculosis, as well as to select potential drug or vaccine candidates. In addition, we discuss the genes engaged in the persistence to get more insights into resuscitation and persister cell formation. The in-depth understanding of persistent cells of mycobacteria can certainly unravel novel ways to target the pathogen and tackle its persistence.Entities:
Keywords: Mycobacterium tuberculosis; antibiotic tolerance; host immune system; in vitro stress models; persistence; resuscitation; therapeutic approaches; tuberculosis biomarkers
Mesh:
Substances:
Year: 2021 PMID: 34637683 PMCID: PMC8565819 DOI: 10.1080/21505594.2021.1990660
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Various stress models generated to study the M. tb persistence with their detailed information
| S. no. | Stress model | Type of model | Stress conditions | Description | References |
|---|---|---|---|---|---|
| 1. | Nutrient starvation model | Nutrient deprivation | Gene expression profiling of an exponential-phase culture of | [ | |
| 2. | Hypoxic Wayne model | Gradual oxygen depletion, stationary phase | Gene expression analysis of | [ | |
| 3. | Enduring Hypoxic Response (EHR) model | Consistent oxygen depletion | Transcriptomic profiling of | [ | |
| 4. | Drug persister model | Antibiotics stress | Transcriptome analysis of two weeks old culture of | [ | |
| 5. | Granuloma model | Hypoxia, oxidative stress, nutrient starvation, acidic pH, antibiotic stress | Gene expression analysis of | [ | |
| 6. | Lysosomal | Hypoxia, nitric oxide, iron limitation, acidic pH, nutrient starvation, stationary phase | Transcriptomic sequence analysis of | [ | |
| 7. | Lipid-rich dormancy model | Lipid-rich (cholesterol and fatty acids) environment, hypoxia, stationary phase | Differential gene expressions of | [ |
Figure 1.The different stress models imitating the granuloma formed in the host infected with M. tb, aid to identify the putative genes involved in the persistence of pathogen
Figure 2.Stress conditions induce persistence in the M. tb that is brought by the interplay of different genes belonging to various essential pathways of the pathogen
Various genes of M. tb that are induced under mentioned stressful conditions and are known to be involved in persistence of the pathogen are listed
| Rv no. | Gene name | Functional product | Function | Induction conditions | References |
|---|---|---|---|---|---|
| Rv0467 | Isocitrate lyase | Involved in glyoxylate cycle | Low pH, low oxygen, macrophage infections, | [ | |
| Rv1212c | Putative glycosyl transferase | Probably involved in cellular metabolism | Low oxygen | [ | |
| Rv2780 | L-alanine dehydrogenase | Involved in cell wall synthesis | Low oxygen, nutrient starvation | [ | |
| Rv2583c | Probable GTP pyrophosphokinase | Involved in the metabolism of ppGpp | Nutrient starvation, low oxygen | [ | |
| Rv2109c | Proteasome α-subunit | Protein degradation | Reactive nitrogen intermediates, oxidative stress | [ | |
| Rv2110c | Proteasome β-subunit | Protein degradation | Reactive nitrogen intermediates, oxidative stress | [ | |
| Rv0363c | Fructose-1,6-bisphosphate aldolase | Involved in glycolysis | Low oxygen, stationary phase, change in carbon source | [ | |
| Rv1568 | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase | Bioconversion of pimelate into dethiobiotin | Stationary phase | [ | |
| Rv2438c | Glutamine dependent NAD synthetase | Biosynthesis of NAD | - | [ | |
| Rv2702 | Polyphosphate glucokinase | Phosphorylation of glucose by using polyphosphate or ATP | - | [ | |
| Rv0650 | Glucokinase | Predicted role in sugar metabolism and regulation | - | [ | |
| Rv1620c | ATP binding ABC transporter CydC protein | Involved in cytochrome biogenesis | Low oxygen, nitric oxide | [ | |
| Rv0126 | Trehalose synthase | Biosynthesis of trehalose | - | [ | |
| Rv2031c | Heat shock protein | Proposed role in the maintenance of long-term viability or replication during latent or initial infections, respectively | Low oxygen, nutrient starvation, macrophage infection, stationary phase | [ | |
| Rv0251c | Heat Shock protein | Involved in the initial step of translation at high temperature | High temperature, nutrient starvation | [ | |
| Rv0353 | Probable heat shock protein transcriptional repressor | Involved in the transcriptional repression of heat shock protein | High temperature | [ | |
| Rv2623 | Universal stress protein family protein TB31.7 | Function unknown | Low oxygen, nitric oxide, macrophage infection | [ | |
| Rv3416 | Transcriptional regulatory protein WhiB-like WhiB3 | Involved in transcriptional mechanisms | Low pH, nutrient, starvation, phosphate starvation | [ | |
| Rv3133c | Two component transcriptional regulatory protein | Regulatory part of two component system devR-devS | Low oxygen, nutrient starvation, nitric oxide | [ | |
| Rv3583c | Transcriptional regulatory protein | Regulation of rRNA transcription | DNA damage and nutrient starvation | [ | |
| Rv1221 | Alternative RNA polymerase sigma factor | Promotes the attachment of RNA polymerase to transcriptional initiation site | Nutrient starvation, macrophage infections, high temperature, low pH, detergent stress | [ | |
| Rv3223c | Alternative RNA polymerase sigma factor | Regulation of thioredoxin cycling in oxidative stress response | Macrophage infections, high temperature, low oxygen | [ | |
| Rv0470c | Cyclopropane synthase | Involved in the synthesis and modifications of mycolic acid | Low temperature | [ | |
| Rv3130c | Triacylglycerol synthase 1 | Involved in the synthesis of triacylglycerol | Low oxygen, low pH, low nutrient, high CO2 | [ | |
| Rv3546 | Acetoacetyl-CoA thiolase | Involved in β-oxidations of side chains of cholesterol | Cholesterol, human macrophages | [ | |
| Rv3526 | Oxygenase component of 3-ketosteroid 9α-hydroxylase | Involved in cholesterol catabolism | Nutrient starvation | [ | |
| Rv3571 | Reductase component of 3-ketosteroid 9α-hydroxylase | Involved in cholesterol catabolism | Microaerophilic conditions, nitrosative stress | [ | |
| Rv3568c | Extradiol dioxygenase | Involved in cholesterol catabolism | - | [ | |
| Rv0955 | Probable conserved integral membrane protein | Probably involved in cell division | Magnesium limitation, low pH | [ | |
| Rv3671c | Membrane associated serine protease | Hydrolysis of peptides/ proteins at serine residue | Low pH, oxidative stress | [ | |
| Rv1477 | Peptidoglycan hydrolase | Involved in hydrolysis of peptidoglycan | Low pH | [ | |
| Rv3717 | Amidase | Involved in hydrolysis of peptidoglycan peptide stems | - | [ | |
| Rv0930 | Phosphate transport system permease protein | Involved in active transport of inorganic phosphate and substrate across the membrane | Nutrient starvation | [ | |
| Rv3301c | Phosphate transport system transcriptional regulatory protein | Transcriptional regulation of inorganic phosphate | Nutrient starvation | [ | |
| Rv0821c | Phosphate transport system transcriptional regulatory protein | Transcriptional regulation of inorganic phosphate | Nutrient starvation | [ | |
Functional analysis of M. tb persistence genes through mutational, deletion, and overexpression studies
| Gene | Information from mutational and expression studies | References |
|---|---|---|
| Rv0467 ( | Mutant displays attenuated persistence in activated macrophages and during chronic phase of mice infection | [ |
| Rv1212c ( | Inactivation reduces glucan content and mutant is unable to persist in chronic mice infection | [ |
| Rv2780 ( | Mutant shows delayed recovery from the non-replicating persistence state | [ |
| Rv2583c ( | Deletion reduces long-term survival | [ |
| Rv2109c ( | Needed for persistence in chronic infection of mice | [ |
| Rv2110c ( | Required for persistence in chronic infection of mice | [ |
| Rv0363c ( | Mutant shows attenuated persistence in chronically infected mice | [ |
| Rv1568 ( | Necessary for establishment of persistence in mice | [ |
| Rv2438c ( | Inactivation reduces the long term survival | [ |
| Rv2702 ( | Double mutant has impaired persistence as demonstrated in chronically infected mice | [ |
| Rv1620c ( | Gene mutation enhances the killing of | [ |
| Rv0126 ( | Deletion mutant shows increased rate of mice survival | [ |
| Rv2031c ( | Deletion mutant shows increased bacterial growth upon tuberculosis infection in mice as well as in resting and activated macrophages | [ |
| Rv0251c ( | Increased expression rapidly after entering the host cell during hypoxia and macrophage infection | [ |
| Rv0353 ( | Inactivation reduces the persistence ability | [ |
| Rv2623 ( | Deletion increases the bacterial growth and fails to establish a chronic tuberculosis infections in animals | [ |
| Rv3416 ( | Mutant shows attenuated persistence in macrophages and guinea pigs model of infection | [ |
| Rv3133c ( | Inactivation reduces the | [ |
| Rv3583c ( | Deletion reduces the bacterial survival in acute and chronic infection of mice | [ |
| Rv1221 ( | Deletion mutant had reduced persistence in macrophages and in chronically infected mice | [ |
| Rv3223c ( | Deletion mutant causes increased apoptosis in non-human primate model | [ |
| Rv0470c ( | Inactivation reduces the persistence in mice | [ |
| Rv3130c ( | Mutant decreases accumulation of TAG | [ |
| Rv3546 ( | Attenuated phenotype in chronic phase of | [ |
| Rv3526 ( | Mutants are unable to persist in acute and chronic phase of mice infection | [ |
| Required to persist in IFN-γ activated macrophages and in lungs of chronically infected mice | [ | |
| Rv3568c ( | Mutants unable to persist in lungs of guinea pig | [ |
| Rv0955 ( | Required for persistence in chronically infected mice | [ |
| Rv3571c ( | Deletion lowers the persistence ability in the chronic phase of mice infection | [ |
| Rv1477 ( | Mutant shows attenuated persistence in chronic phase of mice infection | [ |
| Rv3717 ( | Required for persistence in chronic phase of mice infection | [ |
| Rv0930 ( | Inactivation decreases the persistence in mice | [ |
| Rv3301c ( | Disruption decreases the persistence in chronically infected mice | [ |
| Rv0821c ( | ||
Numerous potential drug and vaccine candidates for M. tb that have been developed recently with their respective stages of clinical trials are listed
| Therapeutic regimens | Formulation of therapeutic regimens | Clinical trials |
|---|---|---|
| DOLPHIN IMPAACT4TB | Isoniazid and rifapentine | Phase I/II |
| IMPAACT P2001 | Isoniazid and rifapentine | Phase I/II |
| TBTC Study 35 | Isoniazid and rifapentine | Phase I/II |
| A5279/BRIEF TB | Isoniazid and rifapentine | Phase III |
| A5300B/I2003/PHOENIx | Delamanid | Phase III |
| CORTIS | Isoniazid and rifapentine | Phase II/III |
| TB-CHAMP | Levofloxacin | Phase III |
| TBTC study 37/ASTERoid | Rifapentine | Phase II/III |
| V-QUIN trial | Levofloxacin | Phase III |
| WHIP3TB | Isoniazid and rifapentine | Phase III |
| P1078 IMPAACT/ TB APPRISE | Isoniazid | Phase IV |
| Ad5Ag85A | Replication-deficient human adenovirus serotype-5 vector expressing Ag85A antigen of | Phase I |
| H1:IC3122 | Recombinant fusion protein ESAT-6 and Ag85B of | Phase I |
| H4:IC3122 | Recombinant fusion protein TB10.4 and Ag85B of | Phase I |
| AEC/BC02 | Ag85B antigen and Fusion protein of CFP-10 and ESAT-6 of | Phase I |
| AERAS-42222 | Recombinant BCG vaccine expresses Ag85A, Ag85B, and Rv3407 antigens mixed with perfringolysin | Phase I |
| AERAS-40221 | Adenovirus serotype 35 (Ad35) expressing Ag85A, Ag85B, and TB10.4 antigens of | Phase I |
| ChAdOx185A – MVA85A21 | Replication-deficient chimpanzee adenovirus/ modified vaccinia Ankara virus vector expressing Ag85A antigen of | Phase I |
| GamTBvac22 | Fusion of two | Phase IIa |
| ID93:GLA-SE22 | Recombinant fusion protein (ID93) comprises four antigens involved in virulence (Rv2608, Rv3619, Rv3620) and latency (Rv1813) of | Phase IIa |
| MTBVAC | Attenuation via deletions of | Phase IIa |
| RUTI® | Liposome coated cell wall fragments of | Phase IIa |
| TB/FLU-04L21 | Attenuated influenza viral vector expressing Ag85A and ESAT-6 antigens of | Phase IIa |
| Gates MRI-TB01-20123 | Live attenuated | Phase IIb |
| DAR-901 booster24 | Heat killed whole cell or extract of | Phase IIb |
| M72/AS01E22 | Recombinant | Phase IIb |
| H56:IC3122 | Recombinant | Phase IIb |
| BCG Revaccination23 | Live | Phase IIb |
| VaccaeTM24 | Whole cell or extract of | Phase III |
| VPM100223 | Live recombinant | Phase III |
| MIP/Immuvac24 | Heat killed | Phase III |
Inhibitors that target genes involved in M. tb persistence are enlisted with their respective inhibitory (IC50) concentrations
| Inhibitors | Target | Inhibition (IC50) | References |
|---|---|---|---|
| 1-((4 methoxyphenyl)sulfonyl)-4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3- | Lat | 1.04 ± 0.32 µM | [ |
| N-(pyridine-2-yl methyl)-2-(4-(quinolin-4-yl) piperazin-1-yl) acetamide | 1.04 µM | [ | |
| Biphenyl amide DG70 | MenG | > 80 µg/ml | [ |
| 2-Vinyl- | Icl | 10 ± 1.3 µM | [ |
| 3-Nitropropionate | 14.7 ± 1.8 µM | [ | |
| 3-Bromopyruvate | 17.5 ± 1.0 µM | ||
| Itaconic acid | 29.4 ± 4.1 µM | ||
| Methyl-4-(4-methoxyphenyl)-4-oxobut-2-enoate | 250 ± 7.0 µM | ||
| Lead 1 | Ald | 35.54 ± 0.0033 µM | [ |
| Lead 2 | 80.37 ± 0.010 µM | ||
| Lead 3 | 51.53 ± 0.0048 µM | ||
| Lead 4 | 36.84 ± 0.030 µM | ||
| Lead 5 | 73.84 ± 0.0232 µM | ||
| Compound X9 | RelA | 4.8 µM | [ |
| 8-Hydroxyqunoline carboxylic acid | Fba | 10 ± 1 µM | [ |
| Compound 1 | 0.0016 µM | [ | |
| Compound 2 | 0.185 µM | ||
| Compound 3 | 0.12 µM | ||
| Compound 4 | 0.31 µM | ||
| Compound 1ʹ8 | 0.013 µM | ||
| Compound 2ʹ8 | 0.17 µM | ||
| 4-(Benzothioazole-2-yl) pentenoic acid | BioA | 153 nM | [ |
| Dihydro-4-pyridone | 3.9 ± 1.2 mM | [ | |
| Compound A35 | 88.16 µM | [ | |
| Compound A36 | 28.94 µM | ||
| Compound A65 | 114.42 µM | ||
| Urea sulfonamide analog 4 f | NadE | 90 ± 5 µM | [ |
| Phenylcoumarin derivative | DosR | < 26.2 µM | [ |
| Artemisinin (HC101A) | 10 µM | [ | |
| HC102A | 10 µM | ||
| HC103A | 10 µM | ||
| HC102A | DosS | 1.9 µM | |
| HC103A | 0.5 µM |